IGF-1 LR3 has no human clinical trials, so its side-effect profile in people is uncharacterized. What can be stated comes from the biology of IGF-1 signaling rather than from studies of this analog in humans.[1][2]
Reviewed for accuracy · Last reviewed July 8, 2026IGF-1 lowers blood glucose, so hypoglycemia is a recognized risk of raising IGF-1 activity: symptoms can include shakiness, sweating, confusion, and in severe cases loss of consciousness. This is the most concrete near-term safety concern.
A second, more theoretical concern runs through all IGF-1 signaling. The IGF-1 receptor pathway has been reviewed as crucial for tumour transformation and the survival of malignant cells, so any agent that amplifies it raises a proliferative or cancer-growth concern. This is a concern about the pathway, not evidence that IGF-1 LR3 causes cancer in people, which has not been studied.
Because human safety data is absent, there is no established management protocol. Anyone considering IGF-1 LR3 should understand that both the hypoglycemia risk and the theoretical proliferative concern are reasons the compound stays firmly in research-only territory.
This page is an independent educational reference and is not medical advice, and does not indicate any approval status for any use. IGF-1 LR3 is a research chemical with no human trials. Talk to a doctor before considering any compound.